LLY Stock Analysis — Eli Lilly and Company
Sector: Healthcare
AI Verdict
LLY trades at 24.9x next year's earnings with blockbuster growth expected, so you're paying up for a pipeline that has to keep delivering to justify the premium.
Competitive Moat
Eli Lilly owns a defensible moat through its proprietary drug portfolio, especially in diabetes and obesity treatments like Mounjaro, which benefit from years of clinical data and regulatory exclusivity. Its scale and pipeline depth make it hard for rivals to replicate its innovation pace or match its entrenched physician relationships.
Summary
LLY is in focus as analysts expect 51.8% EPS growth next year, driven by surging demand for its new obesity and diabetes drugs.
Where It Stands
LLY has returned 49.57% over the past year, trades at 24.9x next year's earnings versus a healthcare median of 22x, and its RSI of 67.6 signals elevated momentum with pullback risk.
Key Metrics
- RSI: 67.6 — Near Overbought
- Trailing P/E: 37.8x
- Forward P/E: 24.9x
- PEG Ratio: 0.73
- Earnings Growth: +0.5%
- Market Cap: $1.00T
- 1-Year Return: 49.57%
Analyst Consensus
30 Buy · 8 Hold · 1 Sell (39 analysts)
Bull Case
You're paying 24.9x forward earnings for a company expected to grow EPS by 51.8% in the next year, making it cheap for the growth on offer if its drug pipeline delivers.
Bear Case
With an RSI of 67.6 and a forward P/E still above the sector median, a pullback to sector multiples would mean a 12%+ valuation drop even if growth materializes.
Catalyst to Watch
FDA approvals or clinical trial readouts for new drugs could either reinforce or undermine the 51.8% EPS growth expectation.